GGHC
KYMR icon

Gilder Gagnon Howe & Co’s Kymera Therapeutics KYMR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3M Sell
229,053
-6,380
-3% -$548K 0.27% 94
2026
Q1 		$19.6M Sell
235,433
-4,483
-2% -$355K 0.24% 87
2025
Q4 		$18.7M Sell
239,916
-6,788
-3% -$458K 0.2% 93
2025
Q3 		$14M Sell
246,704
-82,316
-25% -$3.71M 0.14% 106
2025
Q2 		$14.4M Buy
329,020
+10,639
+3% +$366K 0.15% 98
2025
Q1 		$8.71M Sell
318,381
-7,968
-2% -$290K 0.11% 110
2024
Q4 		$13.1M Buy
326,349
+35,009
+12% +$1.58M 0.14% 105
2024
Q3 		$13.8M Buy
291,340
+160,611
+123% +$7.09M 0.17% 108
2024
Q2 		$3.9M Sell
130,729
-2,260
-2% -$78.2K 0.05% 154
2024
Q1 		$5.35M Buy
+132,989
New +$4.76M 0.07% 148
2023
Q4 		– Sell
-81,865
Closed -$1.14M – 263
2023
Q3 		$1.14M Sell
81,865
-6,867
-8% -$138K 0.02% 205
2023
Q2 		$2.04M Sell
88,732
-764
-0.9% -$21.9K 0.03% 198
2023
Q1 		$2.65M Sell
89,496
-690
-0.8% -$22.3K 0.04% 161
2022
Q4 		$2.25M Buy
90,186
+8,992
+11% +$240K 0.04% 167
2022
Q3 		$1.77M Sell
81,194
-13,879
-15% -$366K 0.03% 176
2022
Q2 		$1.87M Sell
95,073
-19,433
-17% -$454K 0.03% 177
2022
Q1 		$4.85M Sell
114,506
-5,447
-5% -$230K 0.04% 180
2021
Q4 		$7.62M Sell
119,953
-11,741
-9% -$684K 0.04% 191
2021
Q3 		$7.74M Buy
131,694
+23,116
+21% +$1.34M 0.04% 218
2021
Q2 		$5.27M Buy
+108,578
New +$4.71M 0.03% 252

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Gilder Gagnon Howe & Co's KYMR Position: Q2 2026 in Review

Gilder Gagnon Howe & Co reduced its Kymera Therapeutics (KYMR) stake by 2.7% in Q2 2026, selling an estimated $548K and leaving 229,053 shares worth $26.3M. The position accounts for 0.27% of the portfolio, ranked #94.

Gilder Gagnon Howe & Co first reported a position in KYMR in Q2 2021 and has held it in 20 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Gilder Gagnon Howe & Co held 229,053 shares of Kymera Therapeutics worth $26.3M as of Q2 2026.
  • Gilder Gagnon Howe & Co sold 6,380 Kymera Therapeutics shares in Q2 2026, an estimated $548K.
  • Kymera Therapeutics made up 0.27% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #94 holding.
  • Gilder Gagnon Howe & Co first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.